Successful Treatment of Congenital Systemic Juvenile Xanthogranuloma With Langerhans Cell Histiocytosis???Based Chemotherapy

2004 ◽  
Vol 26 (6) ◽  
pp. 371-374 ◽  
Author(s):  
Takuya Nakatani ◽  
Akira Morimoto ◽  
Ryuichi Kato ◽  
Sachiko Tokuda ◽  
Tohru Sugimoto ◽  
...  
2008 ◽  
Vol 35 ◽  
pp. 50-54 ◽  
Author(s):  
Don T. Tran ◽  
Gregory M. Wolgamot ◽  
John Olerud ◽  
Stan Hurst ◽  
Zsolt Argenyi

Author(s):  
Maurizio Aricò ◽  
Cor van den Bos ◽  
Sheila Weitzman

This chapter summarizes the clinical spectrum of the histiocytic disorders—Langerhans cell histiocytosis (LCH), haemophagocytic lymphohistiocytosis (HLH), and some uncommon histiocytic disorders, including juvenile xanthogranuloma (JXG) and Rosai–Dorfman disease—as well as the current diagnostic and therapeutic approaches in these diseases. Multiple activating mutations in the RAS–RAF–MEK–ERK pathway have recently been described in LCH. Their role in the pathophysiology of the disorder and in targeted therapy is reviewed. This chapter explains the differences between primary and secondary HLH, and reviews the genetic abnormalities playing a role in both forms of HLH.


2008 ◽  
Vol 144 (5) ◽  
Author(s):  
Esther von Stebut ◽  
Simin Schadmand-Fischer ◽  
Wolfgang Bräuninger ◽  
Andreas Kreft ◽  
Claus Doberauer ◽  
...  

2001 ◽  
Vol 26 (5) ◽  
pp. 391-394 ◽  
Author(s):  
P. H. Hoeger ◽  
C. Diaz ◽  
M. Malone ◽  
J. Pritchard ◽  
J. I. Harper

2010 ◽  
Vol 119 (2) ◽  
pp. 134-140 ◽  
Author(s):  
Ambrogio Fassina ◽  
Andrea Olivotto ◽  
Rocco Cappellesso ◽  
Roberto Vendraminelli ◽  
Matteo Fassan

1998 ◽  
Vol 36 (6) ◽  
pp. 1229-1240 ◽  
Author(s):  
Ahmed A. Hidayat ◽  
Mahmood F. Mafee ◽  
Nora V. Laver ◽  
Samir Noujaim

Sign in / Sign up

Export Citation Format

Share Document